performed and were unremarkable. She had a mild anaemia and persistently raised CRP. Her initial autoimmune screen showed no abnormality. An outpatient CT chest, abdomen and pelvis showed a small pericardial effusion and noevidence of malignancy. In July 2014 she was reviewed in the rheumatology clinic and in view of her symptom profile and persistently raised inflammatory markers in the absence of infection, this raised the possibility of a systemic inflammatory problem related to a vasculitis. The recent CT imaging was reviewed at the rheumatology/radiology MDT and the radiologists felt that there was some probable inflammatory change in the aorta and some wall thickening. Further investigations with PET CT confirmed inflammatory changes in the large vessels and IgG subclasses were elevated at 2.06g/L. She was started on treatment for LVV and possible IgG4 disease, initially with 40mg prednisolone and MMF was later introduced. A repeat PET in May 2015 was normal. In January 2016 she developed sudden ataxia, hyporeflexia and weakness. She was found to have positive anti-gq1 antibodies and diagnosed with Miller-Fisher syndrome. Her symptoms resolved with an increase in the prednisolone dose. She had 3 further hospital admissions, each with similar symptoms of collapse and loss of consciousness, which was subsequently felt to be due to AI. Discussion: In this patient presenting with fevers and raised inflammatory markers, the initial investigations were rightly aimed at trying to identify a source of infection as this is the main concern in a patient with an ongoing pyrexia. Reviewing the images in clinic and at our MDT meeting identified the thickened aortic wall. This was key in providing further information as to what might be the cause of the patient's presentation and led us to order the appropriate and more detailed investigations in the form of PET CT and IgG subclasses. It was not possible in this case to get a histological diagnosis and therefore, based on the elevated IgG subclasses and PET findings, a presumptive diagnosis of IgG4 related disease and LVV was made. The initial treatment choice of prednisolone 40mg is based on current practice for treating LVV. In view of the IgG4 disease and after discussion with the Immunologists, it was decided that MMF would be the most appropriate steroid-sparing agent. This case highlights the fact that making adiagnosis of largevesselvasculitis is somewhatdifficult due to the non-specific clinicalpresentationsand laboratory findings. Once the diagnosis was made, this raised the question as to whether the pulmonary hypertension was in any way connected to the LVV or coincidental. This case also highlights the fact that patients with several immune-related diseases can develop further autoimmune conditions. In this case she was initially diagnosed with a LVV and IgG4-related disease then Miller-Fisher syndrome and following that adrenal insufficiency. Is this phenomenonbecoming more common inclinicalpractice? One other point for discussion is the choice of steroid-sparing agent, in this case we opted for MMF. Is there a case forrituximab in this patient? Key learning points: This case illustrates the fact that looking at previous imaging was crucial at providing further information and decide on further imaging that would aid in the diagnosis. The CT images were reviewed with the relevant laboratory findings, clinical picture and asking the right questions to the radiologists. In this case, we asked them to have a look at the large vessels in more detail as this can sometimes be missed and not properly looked at if the radiologists are not asked to specifically look at the large vessels. The differential diagnosis for these patients are broad and include infection, malignancy and inflammatory conditions such as a vasculitis or autoinflammatory disorder. Therefore keeping an open mind where these patients are concerned is important, especially in exploring the rarer causes of sucha presentation. There is no single diagnosis to explain all the symptoms experienced by the patient. The presence of one autoimmune disease should alert one to watch for another onein these patients. A multi-disciplinary team approach to the management of these complex patients with several autoimmune disorders, is essential. Reviewing the images with the radiologists helped identify thickening of the aortic wall. The regional immunology team was also involved in discussions about long-term management. The Neurology team was also involved and diagnosed Miller-Fisher syndrome.
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BINOCULAR SIGHT LOSS: UNCOMMON, YET A DEVASTATING COMPLICATION OF GCA
Liubov Borukhson 1 , Abdul Kayani 1 , and Bhaskar Dasgupta 1 1 Rheumatology, Southend University Hospital, Southend, United Kingdom Introduction: GCA (giant cell arteritis) affects cranial branches of the arteries from aortic arch, especially the superficial temporal artery and vessels supplying the eye. Ophthalmic manifestations of GCA are characterised by the vasculitis of the ophthalmic artery and its branches. We present a case of a patient who developed the binocular sequential permanent vision loss secondary to GCA due to the delayeddiagnosis. Case description: A seventy-six year-old lady with a background of type two diabetes mellitus, hypertension and dyslipidemia and hemicolectomy for appendix tumour two years ago (no recurrence) was admitted with blurring of vision in the eye. She did not complain about other symptoms, however, on direct questioning she admitted six weeks history of weight loss (2.5 stones), severe tiredness and occasional night sweats, mild left sided temporal headache. She was initiated on 60mg of prednisolone. One week prior to admission she had right eye CRAO diagnosed by the ophthalmology team with preceding three weeks history of right eye blurring of vision. CRP at that time was 12 g/L and GCA was not considered likely. Following her permanent right sided vision loss, she was referred to stroke team for further management and was given aspirin. Her CT and MRI brain scans were unremarkable, USS carotid arteries revealing diffuse intimal thickeningin all the arteries of the neck. On assessment in the rheumatology fast track clinic she denied any associated jaw/tongue/arms claudication and no proceeding or historical PMR symptoms. She had mild left sided temporal artery tenderness and decreased temporal artery pulses bilaterally, no vision in the right eye along with the blurring in the left eye. There were no audible bruits in carotid, axillary, femoral arteries. Her acute phase maker (CRP) was mild but persistently elevated with a maximum level of 12 g/L for one week prior the admission. USS showed features consistent with GCA with extensive non-compressible halo signs in temporal arteries and its branches bilaterally. An urgent ophthalmology review revealed AION changes in the left eye, her vision deteriorated over the next forty-eight hours despite the initiation of high dose intravenous methylprednisolone. The patient was also started on tocilizumabinfusion inan attempt to reverse the sight loss. Discussion: The ophthalmic manifestations of GCA range from AION (anterior ischaemic optic neuropathy), CRAO (anterior central retinal artery occlusion), cilioretinal artery occlusion to occipital lobe infarcts, transient monocular vision loss, photopsias or diplopia. Ophthalmic GCA is an emergency and requires urgent ophthalmological evaluations and initiation of treatment with high dose of steroids to avoid permanent loss of vision. The reported incidence of visual symptoms in GCA ranges widely from 12% to 70% of cases. GCA is often associated with constitutional symptoms such as weight loss, night sweats, fevers, systemic inflammatory response with elevated inflammatory markers. However, it had been reportedthat this can be very mild inischaemic GCA. The diagnosis of GCA in this particular case was delayed for approximately six weeks due to the atypical initial presentation with mainly constitutional symptoms and unilateral vision blurring as well as mildly elevated inflammatory markers. A collaboration of three teams (namely ophthalmology, stroke and rheumatology) proved necessary to initiate high dose steroid treatment and tocilizumab. However, patient still suffered from permanent binocular vision loss. She was registered blind and will infuturerequire extensive physical and psychological support. Key learning points: Despite the recent advances and increased awareness with good availability of fast track GCA services, cases of bilateral blindness are still observed. This is due to a lack of awareness of atypical non-cranial symptoms that frequently accompany a GCA ischaemic presentation. Inflammatory markers are often only mildly elevated in such cases. We suggest a heightened public and professional awareness program to mitigate this irreversible disastrous complication. Conflicts of interest: The authors have declared no conflicts of interest.
A CASE FOR CONTINUING TOCILIZUMAB BEYOND 12 MONTHS IN GIANT CELL ARTERITIS?
Caroline Ming 1 , and John Stack 1 1 Rheumatology Department, King's College Hospital, London, United Kingdom Introduction: This case discusses a 60-year-old old gentleman who had aggressive disease and severe complications of giant cell arteritis. Shortly after diagnosis of GCA, he had an aortic dissection which was successfully repaired surgically. Medical therapy was escalated by increasing steroids and initiating tocilizumab, which was continued for one year as per NICE guidance. Within 4 weeks of ceasing tocilizumab, GCA flared symptomatically and serologically. He was promptly restarted on tocilizumab, to which he responded. 2 months later he collapsed, and resuscitation attempts were unsuccessful. Post mortem examination revealed ruptured aortic aneurysm. Case description: A 60-year-old old retired gentleman presented with left sided headache and blurred vision. CRP and ESR were 80 and 100 respectively. Temporal artery biopsy confirmed giant cell arteritis. He commenced 60mg prednisolone with good response and weaned according to BSR guidance. Past medical history included Barrett's oesophagus. He was a non-smoker and had a strong family history of cardiovascular disease. 2 months later, he presented to A&E with central chest pain radiating to the groins and lower limb weakness. CT aortogram demonstrated Type A aorticdissectionextending tothebifurcation.Hewas urgentlytransferred to a tertiary centre and underwent aortic root, ascending aorta and proximal aortic arch replacement with grafts. Rheumatology recommended pulsed IV methylprednisolone and tocilizumab due to aggressive disease. Histopathology from the dissected aorta reported 'degenerative disease and noactive GCA'. In rheumatology clinic 2 weeks later, he was in atrial fibrillation and commenced on apixiban and amiodarone. PET CT performed 6 weeks post-operatively did not show active vasculitis. He remained asymptomatic on tocilizumab with normal inflammatory markers. Prednisolone was weaned in accordance with GiACTa trial. He reverted to sinus rhythm; therefore apixiban and amiodarone werediscontinued. 2 months later he developed acute left sided parasthesiae and weakness due to right thalamicinfarct.He was in AF and CRP was <1. Over the following 6 months, he exhibited no features of active GCA. He suffered attacks of gout therefore prednisolone was increased to 5mg. He completed 12 months of tocilizumab, remaining on low dose prednisolone for gout. Within 1 month he relapsed with night sweats, arm claudication and ESR 97, CRP 247. Temporal ultrasound was negative. He received pulsed IV methylprednisolone and restarted tocilizumab, with promptsymptomatic and serological response. Two months later, he collapsed and suffered cardiac arrest. Post mortem revealed ruptured aortic aneurysm. Discussion: This case highlights a severe case of GCA where the patient succumbed to a recognised but rare complication. Aortic involvement in GCA includes aortitis, dilatation, aneurysm and dissection. However, it is difficult to accurately report the incidence and prevalence as aortic involvement can be asymptomatic. Modern imaging studies have improved detection, demonstrating prevalence in up to 65% of newly diagnosed cases. Interestingly, this patient developed a dissection 2 months post diagnosis; whilst on 40mg prednisolone and demonstrating a clinical response. CRP was normal one week prior. The biopsy specimen did not find vasculitis suggesting the dissection occurred due to damage caused by previous activity. However, we later discovered only 1-2cm of resected aorta was examined, which may have missed patchy inflammation. Tocilizumab was licensed by NICE in 2017, so there are few patients that have received 12 months therapy and long-term remission rates beyond this are still being reported from the GiACTa trial. NICE recommends tocilizumab inrefractory orrelapsing diseaseand this shouldbe stopped after 12 months. Considering he dissected relatively early after diagnosis whilst on 40mg prednisolone, tocilizumab was indicated for refractory disease and toreduce long term steroid burden.
He achieved disease remission which was sustained while tapering steroids. However, on withdrawing tocilizumab at 12 months he quickly relapsed. The departmental decision was to restart tocilizumab. NICE implemented a 12-month stopping rule, therefore how to we proceed in these patientswithaortic complications and high-riskdisease? Stroke and TIA are also reported complications of large vessel vasculitis. Our patient's CRP was normal at time of his stroke. He was in AF, and not on prophylaxis. Ultrasound Doppler's were not performed at the time. It is difficult toconcludewhether this was cardioembolic orrelated tovascular disease inthe absence of anystenotic lesions. Key learning points: Predicting patients at highest risk of aortic complications is challenging. Is there rationale to perform FDG PET in all patients to determine extent of disease? Clearly this isn't feasible in the NHS, in which case should we determine some clear parameters to guide indications for imaging. Cardiovascular risk factors are the only other predictors of dissection in GCA. Retrospectively, we discovered a strong family history of sudden cardiac death from cardiovascular disease onhis paternal side. One must assume he had asymptomatic active aortic disease some time before the onset of his cranial symptoms. This resulted in vascular damage by the time of biopsy, by which time he had been on steroids for a few weeks, and noactive vasculitis was seen. Biopsyspecimens require clear instruction to histopathology and sufficient sample length to avoid false negatives. He was awaiting CT angiogram to observe for further aortic manifestations but unfortunately suffered fatal aneurysm rupture only a few weeks prior. In a subset of patients deemed to be high risk, closer monitoring must be pursued and include imaging. Whilst on treatment, despite normal inflammatory markers and little symptoms, he was having subclinical damage which resulted in ruptured aneurysm. Interestingly, temporal/carotid/axillary artery ultrasound did not show features of vasculitis. Possibly his disease did not affect these vessels. We must also remember that tocilizumab lowers CRP and therefore ESR must bemeasured as well. As this case demonstrates, men in their 50's and 60's are prone to aggressive disease and relapse. NICE guidance implements a 12-month stopping policy; and doesn't cater for these patients. Even though our patient appeared to be in remission, should tocilizumab be continued beyond 12 months in patients with prior aortic disease? We must make clinical decisions on acase by case basis. There is some evidence that abatacept carries less infection related morbidity when compared with tumour necrosis factor (TNF) inhibitors. The efficacy of addition of abatacept to prednisolone in reducing the risk of relapse of GCA is suggested in one study. Abatacept and prednisolone combination did not show higher rate of toxicity when compared to prednisolone alone, including rate of infection. In this context, could abatacept be a choice of treatment in this case? Conflicts of interest: The authors have declared no conflicts of interest.
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